Sequel Med Tech and Senseonics have announced a new collaboration aimed at developing the first automated insulin delivery (AID) system that incorporates a one-year continuous glucose monitoring (CGM) sensor.
The initiative will integrate Sequel’s twiist AID system with Senseonics’ Eversense 365 CGM, offering an extended-use diabetes management solution for individuals with type 1 diabetes.
This integration is set to deliver an automated system that operates alongside a long-duration CGM device, following regulatory approval of Eversense 365 in September 2024. The US Food and Drug Administration’s clearance of Eversense 365 as an integrated CGM (iCGM) system enabled its compatibility with automated insulin platforms such as twiist.
The companies confirmed that the combined technology is scheduled to reach the market in the second quarter of 2025.
The partnership will give users of Sequel’s system the option to pair their insulin delivery with either the Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor. This flexibility is expected to broaden choices in CGM integration.
Senseonics’ Eversense 365, which enables glucose monitoring for up to a full year with a single sensor, is currently the only system of its kind cleared for that duration. Its integration with an AID system aims to provide longer periods of uninterrupted glucose data, reducing the need for frequent sensor replacements and associated disruptions in diabetes care.
Sequel stated that the collaboration is part of its strategic plan to expand CGM compatibility and deliver enhanced personalisation for people managing type 1 diabetes. The initiative is designed to improve user control, offer more flexibility, and facilitate continuous data-based decision-making by incorporating long-term glucose data directly into insulin delivery algorithms.
Development efforts are already underway to ensure seamless functionality between the CGM and AID platforms.
Both companies emphasise that the integration supports broader industry goals of improving accessibility, efficiency, and usability in glucose control technologies. By bringing together a year-long CGM and an automated insulin system, they aim to simplify the user experience and reduce the day-to-day demands typically associated with diabetes care.
